XORTX Therapeutics Inc
Research XORTX Therapeutics Inc (XRTX) on Bullrun: market cap USD 3.06M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXRTX
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.06M
- Financial periodQ1 2026
- Net income-USD 808.47K
- Free cash flow-USD 505.15K
Valuation Snapshot
latest market cap is USD 3.06M.
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus;
Frequently asked questions
What is XORTX Therapeutics Inc's market cap?
XORTX Therapeutics Inc's market capitalization is USD 3.06M.
What does XORTX Therapeutics Inc do?
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout;